- Home
- FINW vs VYGR Comparison
FINW vs VYGR Comparison
Compare FINW & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- VYGR
- Stock Information
- Founded
- FINW 1999
- VYGR 2013
- Country
- FINW United States
- VYGR United States
- Employees
- FINW N/A
- VYGR N/A
- Industry
- FINW Commercial Banks
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- VYGR Health Care
- Exchange
- FINW Nasdaq
- VYGR Nasdaq
- Market Cap
- FINW 242.1M
- VYGR 231.9M
- IPO Year
- FINW 2021
- VYGR 2015
- Fundamental
- Price
- FINW $19.08
- VYGR $4.23
- Analyst Decision
- FINW Buy
- VYGR Strong Buy
- Analyst Count
- FINW 3
- VYGR 7
- Target Price
- FINW $21.67
- VYGR $17.00
- AVG Volume (30 Days)
- FINW 13.2K
- VYGR 557.4K
- Earning Date
- FINW 10-29-2025
- VYGR 11-06-2025
- Dividend Yield
- FINW N/A
- VYGR N/A
- EPS Growth
- FINW N/A
- VYGR N/A
- EPS
- FINW 1.05
- VYGR N/A
- Revenue
- FINW $80,199,000.00
- VYGR $42,580,000.00
- Revenue This Year
- FINW $72.14
- VYGR N/A
- Revenue Next Year
- FINW $47.30
- VYGR $107.10
- P/E Ratio
- FINW $18.24
- VYGR N/A
- Revenue Growth
- FINW 14.76
- VYGR N/A
- 52 Week Low
- FINW $13.49
- VYGR $2.65
- 52 Week High
- FINW $22.49
- VYGR $7.44
- Technical
- Relative Strength Index (RSI)
- FINW 54.44
- VYGR 41.58
- Support Level
- FINW $18.51
- VYGR $4.10
- Resistance Level
- FINW $19.80
- VYGR $4.30
- Average True Range (ATR)
- FINW 0.67
- VYGR 0.26
- MACD
- FINW 0.16
- VYGR -0.10
- Stochastic Oscillator
- FINW 70.29
- VYGR 20.89
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.